Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but ...

Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US and Europe later this year.

Chief Executive Officer Wayne Paterson outlined the company’s DurAVR transcatheter aortic valve replacement (TAVR) program ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

TAVR, a minimally invasive alternative to open‑heart surgery for severe aortic stenosis, has become the global standard for elderly and high‑risk patients.

For a balloon-expandable transcatheter aortic valve replacement (TAVR or TAVI) platform, the much-litigated Myval performed well enough in the COMPARE-TAVI 1 randomized trial, but its rates of ...

The use of transcatheter aortic valve replacement (TAVR) increased among healthier, lower-risk patients younger than 65 between 2012 and 2024, despite a lack of randomized data on this patient ...

New-onset LBBB following TAVR is associated with increased 1-year mortality, rehospitalization, and permanent pacemaker implantation.

A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from aortic regurgitation, a potentially dangerous condition that occurs ...

On August 6, the Federal Trade Commission (FTC) challenged Edwards Lifesciences Corp.'s proposed $945 million acquisition of JenaValve Technology, Inc. The deal would combine the two leading companies ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Indian-made Myval and Myval Octacor were put to the test against Sapien 3 in the noninferiority trial COMPARE TAVI-1. Noninferiority was demonstrated when counting deaths, strokes, moderate or severe ...